Polyrizon

Polyrizon FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Polyrizon (PLRZ) as of Oct 21, 2026 is 135.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 74.24 % — a change of 83.17% (higher).

FCF Conversion

135.98 %

YoY

83.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Polyrizon is 2025 135.98 % . FCF Conversion Rate (FCF/EBITDA) of Polyrizon was 2024 74.24 % . It decreases by 83.17% higher compared to the previous year.

The Polyrizon FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
108.22 USD
Jan 1, 2021
71.87 USD
Jan 1, 2022
145.70 USD
Jan 1, 2023
89.50 USD
Jan 1, 2024
74.24 USD
Jan 1, 2025
135.98 USD
The Polyrizon FCF Conversion history
YEARFCF ConversionYoY
135.98 %+83.17%
74.24 %-17.05%
89.50 %-38.57%
145.70 %+102.73%
71.87 %-33.59%
108.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

FCF Conversion Rate (FCF/EBITDA) of Polyrizon is 135.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Polyrizon changed from 74.24 % to 135.98 %, representing a 83.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Polyrizon since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Polyrizon with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Polyrizon

All Key Metrics — Polyrizon